Trial Profile

A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs THR 317 (Primary)
Indications Diabetic macular oedema
Focus Adverse reactions
Sponsors Oxurion; ThromboGenics

Most Recent Events

06 Jun 2019 according to an Oxurion media release, data from the study were presented at the biannual Retina Meeting (FLORetina 2019).
06 Jun 2019 Results presented in an Oxurion media release.
19 Jul 2018 According to a ThromboGenics media release, results will be presented in an upcoming ophthalmology meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com